Abstract
Parainfluenza virus (PIV) can cause significant morbidity after allogeneic stem cell transplantation (SCT). We report the first use of inhaled DAS181 for PIV in an allogeneic SCT recipient. Symptoms, oxygenation, and pulmonary function tests improved. Nasopharyngeal samples showed a reduction in viral load. DAS181 should be systematically evaluated for severe PIV infection.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Inhalation
-
Antiviral Agents / administration & dosage*
-
Female
-
Humans
-
Immunocompromised Host
-
Middle Aged
-
Nasopharynx / virology
-
Oxygen / blood
-
Parainfluenza Virus 3, Human / isolation & purification
-
Recombinant Fusion Proteins / administration & dosage*
-
Respiratory Function Tests
-
Respirovirus Infections / diagnosis
-
Respirovirus Infections / drug therapy*
-
Respirovirus Infections / pathology
-
Stem Cell Transplantation / adverse effects*
-
Transplantation, Homologous / adverse effects*
-
Treatment Outcome
-
Viral Load
Substances
-
Antiviral Agents
-
Recombinant Fusion Proteins
-
oplunofusp
-
Oxygen